Determination of mitral valve area in patients with mitral stenosis by the flow-convergence—region method during changing hemodynamic conditions

1996 ◽  
Vol 132 (3) ◽  
pp. 633-641 ◽  
Author(s):  
You-Bin Deng ◽  
Masayuki Matsumoto ◽  
Junichi Munehira
1998 ◽  
Vol 135 (2) ◽  
pp. 207-214 ◽  
Author(s):  
Muzaffer Degertekin ◽  
Yelda Basaran ◽  
Murat Gencbay ◽  
Bengi Yaymaci ◽  
Ismet Dindar ◽  
...  

1994 ◽  
Vol 127 (5) ◽  
pp. 1348-1353 ◽  
Author(s):  
Marcus F Stoddard ◽  
Charles R Prince ◽  
Nasar M Ammash ◽  
John L Goad

2017 ◽  
Vol 34 (7) ◽  
pp. 1002-1009 ◽  
Author(s):  
Francisco Sampaio ◽  
Ricardo Ladeiras-Lopes ◽  
João Almeida ◽  
Paulo Fonseca ◽  
Ricardo Fontes-Carvalho ◽  
...  

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yahya Dadjo ◽  
Maryam Moshkani Farahani ◽  
Reza Nowshad ◽  
Mohsen Sadeghi Ghahrodi ◽  
Alireza Moaref ◽  
...  

Abstract Background Rheumatic heart disease (RHD) is still a concerning issue in developing countries. Among delayed RHD presentations, rheumatic mitral valve stenosis (MS) remains a prevalent finding. Percutaneous transvenous mitral commissurotomy (PTMC) is the intervention of choice for severe mitral stenosis (MS). We aimed to assess the mid-term outcome of PTMC in patients with immediate success. Methods In this retrospective cohort study, out of 220 patients who had undergone successful PTMC between 2006 and 2018, the clinical course of 186 patients could be successfully followed. Cardiac-related death, undergoing a second PTMC or mitral valve replacement (MVR) were considered adverse cardiac events for the purpose of this study. In order to find significant factors related to adverse cardiac outcomes, peri-procedural data for the studied patients were collected.The patients were also contacted to find out their current clinical status and whether they had continued secondary antibiotic prophylaxis regimen or not. Those who had not suffered from the adverse cardiac events were additionally asked to undergo echocardiographic imaging, in order to assess the prevalence of mitral valve restenosis, defined as mitral valve area (MVA) < 1.5 cm2 and loss of ≥ 50% of initial area gain. Results During the mean follow-up time of 5.69 ± 3.24 years, 31 patients (16.6% of patients) had suffered from adverse cardiac events. Atrial fibrillation rhythm (p = 0.003, HR = 3.659), Wilkins echocardiographic score > 8 (p = 0.028, HR = 2.320) and higher pre-procedural systolic pulmonary arterial pressure (p = 0.021, HR = 1.031) were three independent predictors of adverse events and immediate post-PTMC mitral valve area (IMVA) ≥ 2 cm2 (p < 0.001, HR = 0.06) was the significant predictor of event-free outcome. Additionally, follow-up echocardiographic imaging detected mitral restenosis in 44 patients (23.6% of all patients). The only statistically significant protective factor against restenosis was again IMVA ≥ 2 cm2 (p = 0.001, OR = 0.240). Conclusion The mid-term results of PTMC are multifactorial and may be influenced by heterogeneous peri-procedural determinants. IMVA had a great impact on the long-term success of this procedure. Continuing secondary antibiotic prophylaxis was not a protective factor against adverse cardiac events in this study. (clinicaltrial.gov registration: NCT04112108).


Sign in / Sign up

Export Citation Format

Share Document